Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy-Reference-Cited by-同舟云学术

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

Published:2015-10 Issue:2 Volume:67 Page:4-17
ISSN:0161-5890
Container-title:Molecular Immunology
language:en
Short-container-title:Molecular Immunology

Author:

Swaika Abhisek,Hammond William A.,Joseph Richard W.

Publisher

Elsevier BV

Subject

Molecular Biology,Immunology

Reference131 articles.

1. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction;Abiko;Clin. Cancer Res.,2013

2. Tumor antigen-specific CD8T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired;Ahmadzadeh;Blood,2009

3. BCG immunotherapy of bladder cancer: 20 years on;Alexandroff;Lancet,1999

4. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC);Amin;ASCO Meet. Abstr.,2014

5. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells;Andorsky;Clin. Cancer Res.,2011

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exosomes of immune cell origin and their therapeutic potential for tumors;VIEW;2024-09-02

2. From antigen uptake to immune modulation: the multifaceted potential of peptide nanofibers as vaccine nanocarriers;Materials Advances;2024

3. Navigating Molecular Pathways: An Update on Drugs in Colorectal Cancer Treatment;Current Topics in Medicinal Chemistry;2023-12

4. An Innovative Approach to Address Neurodegenerative Diseases through Kinase-Targeted Therapies: Potential for Designing Covalent Inhibitors;Pharmaceuticals;2023-09-13

5. Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2′-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors;Journal of Medicinal Chemistry;2023-07-26